CRISPR Therapeutics (CRSP) is expected to finally start booking real revenue from its Casgevy treatment next year. The drug was approved in 2023, but the custom treatment takes about a year per patient, so revenue recognition is delayed. Vertex (VRTX) saw Casgevy revenue jump to $76M last quarter. Analysts think CRSP's reported revenue will grow from $40M this year to $156M next year. Viking Therapeutics (VKTX) is making progress on their GLP-1 weight-loss drug, VK2735. They want it to be a monthly maintenance injection rather than the weekly shots required by Eli Lilly (LLY) and Novo Nordisk (NVO). They are also starting late-stage trials for a pill version later this year. The stock has a consensus price target around $93.